Epstein-Barr virus-induced molecule 2 (EBI2) (also known as G-protein-coupled receptor 183) is a G-protein-coupled receptor (GPCR) that is best known for its role in B cell migration and localization. Our recent deorphanization effort led to the discovery of 7␣,25-dihydroxycholesterol (7␣,25-OHC) as the endogenous ligand for EBI2, which provides a tool for mechanistic studies of EBI2 function. Because EBI2 is the first GPCR known to bind and to be activated by an oxysterol, the goal of this study was to understand the molecular and structural bases for its ligand-dependent activation; this was achieved by identifying structural moieties in EBI2 or in 7␣,25-OHC that might affect receptor-ligand interactions. By using a series of chemically related OHC analogs, we demonstrated that all three hydroxyl groups in 7␣,25-OHC contributed to ligandinduced activation of the receptor. To determine the location and composition of the ligand binding domain in EBI2, we used a site-directed mutagenesis approach and generated mutant receptors with single amino acid substitutions at selected positions of interest. Biochemical and pharmacological profiling of these mutant receptors allowed for structure-function analyses and revealed critical motifs that likely interact with 7␣,25-OHC. By using a hybrid ␤ 2 -adrenergic receptor-C-X-C chemokine receptor type 4 structure as a template, we created a homology model for EBI2 and optimized the docking of 7␣,25-OHC into the putative ligand binding site, so that the hydroxyl groups interact with residues Arg87, Asn114, and Glu183. This model of ligand docking yields important structural insight into the molecular mechanisms mediating EBI2 function and may facilitate future efforts to design novel therapeutic agents that target EBI2.
Introduction
Epstein-Barr virus-induced molecule 2 (EBI2), also known as GPR183, is a GPCR that was originally identified as a gene that is highly up-regulated upon Epstein-Barr virus infection (Birkenbach et al., 1993) . EBI2 is expressed most abundantly in lymphoid tissues, such as spleen and lymph nodes (Birkenbach et al., 1993; Rosenkilde et al., 2006) . Although it is classified as a class A rhodopsin-like GPCR (Vassilatis et al., 2003) , EBI2 lacks strong sequence similarity to most other GPCRs. The closest homolog is GPR18, which exhibits 52% similarity to EBI2 (Benned-Jensen and Rosenkilde, 2008) . Previous studies showed that EBI2 signals through G␣ i but not G␣ s or G␣ q (Rosenkilde et al., 2006; Hannedouche et al., 2011; Liu et al., 2011) . Activation of EBI2 leads to adenylate cyclase inhibition and subsequent reduction of cAMP production. EBI2 also was reported to activate extracellular signal-regulated kinase (Benned-Jensen et al., 2011) .
Significant progress has been made in determining the functional significance of EBI2 in the immune system (Gatto et al., 2009 (Gatto et al., , 2011 Pereira et al., 2009 Pereira et al., , 2010 Hannedouche et al., 2011; Kelly et al., 2011; Liu et al., 2011) . It is now widely acknowledged that EBI2 expression and EBI2-mediated chemotaxis represent important molecular mechanisms for directing follicular B cell migration and localization. Up-regulation of EBI2 expression in B cells during early stages of an immune response promotes the movement of activated B cells to the outer follicle and interfollicular regions, whereas down-regulation of EBI2 expression allows B cells to move to the center of follicles for germinal center formation. These carefully orchestrated events are part of an intricate, wellbalanced network of chemokine receptors that includes EBI2, CXCR5, C-C chemokine receptor type 7, and CXCR4 (Gatto et al., 2011; Kelly et al., 2011) . Together, they are responsible for providing B cells with a precise plan for mounting correct antibody responses when necessary. B cells from EBI2-deficient mice were reported to exhibit abnormal migration patterns and reduced antibody responses (Liu et al., 2011) .
We identified an oxysterol, 7␣,25-OHC, as the most likely endogenous ligand for EBI2 (Liu et al., 2011) . 7␣,25-OHC (structure shown in Fig. 2A ) is an oxygenated derivative of cholesterol and is converted endogenously from 25-OHC by the enzyme CYP7B1 (Rose et al., 1997) . 7␣,25-OHC binds EBI2 with a dissociation constant of 450 pM and activates EBI2 with an EC 50 of 140 pM, which makes it more potent than the other oxysterols we tested. Functionally, 7␣,25-OHC directs B cell migration both in vitro and in vivo. Pharmacological blockade of 7␣,25-OHC synthesis disrupts B cell migration patterns, consistent with findings observed with B cells from EBI2-deficient mice (Liu et al., 2011) . Similar results were reported by Hannedouche et al. (2011) .
Identification of 7␣,25-OHC as the endogenous ligand for EBI2 revealed an important link between EBI2 and its known function in the immune system and allowed us to measure receptor activation quantitatively in vitro. Previous structure-function studies with EBI2 were focused largely on investigating its constitutive activity. Those studies revealed important structural motifs for the ligand-independent activity of the receptor and suggested potential molecular constraints during receptor transition from the inactive conformation to the active conformation (Benned-Jensen and Rosenkilde, 2008; Benned-Jensen et al., 2011) . We decided to explore the molecular mechanisms of ligand-dependent activation of EBI2 by using 7␣,25-OHC as a tool. We showed previously that the hydroxyl groups in the 7Ј-and 25Ј-positions of 7␣,25-OHC are important for ligand activity (Liu et al., 2011 ). Here we demonstrate that the 3Ј-hydroxyl group, which is native to the steroidal body of cholesterol, is also a critical component of receptor-ligand interactions. To distinguish the structural motifs in EBI2 that are important for receptor activity, we used a mutagenesis approach and made single amino acid changes at various positions in the receptor, the majority of which were side-chain eliminations with Ala substitutions. Transmembrane region mutations were proposed on the basis of sequence alignment of EBI2 with GPCRs with known X-ray crystal structures. Mutations in the extracellular loops were proposed mainly on the basis of conservation among different species (Fig. 1) . By measuring receptor expression, receptor activation, and radioligand binding, we characterized the pharmacological profiles of mutant receptors and identified key residues mediating receptor function. These structure-activity data were incorporated into a homology model of EBI2. By using a hybrid ␤ 2 AR-CXCR4 structure as a template, we were able to dock 7␣,25-OHC and to define the putative ligand binding site. This information may facilitate the rational design of smallmolecule compounds to serve as agonists or antagonists of EBI2.
Materials and Methods

Materials.
Unless indicated otherwise, all materials were purchased from Sigma-Aldrich (St. Louis, MO). 7␣,25-OHC, 7␣,27-OHC, and 7␣,27-dihydroxy-4-cholesten-3-one were purchased from Avanti Polar Lipids (Alabaster, AL).
3 H-labeled 7␣,25-OHC (specific activity, 30 Ci/mmol) was custom-synthesized by Moravek Biochemicals (Brea, CA). Cell culture reagents were purchased from Thermo Fisher Scientific (Waltham, MA). Lipofectamine transfection reagent and anti-V5 mouse monoclonal antibody were purchased from Invitrogen (Carlsbad, CA).
Site-Directed Mutagenesis of EBI2. The coding region of human ebi2 (GenBank accession no. NM_004951.4) with a V5 tag at the N terminus (V5-ebi2) was cloned into the mammalian expression vector pCIneo, as described (Liu et al., 2011) . For site-directed mutagenesis, wild-type V5-ebi2 served as a template for polymerase chain reaction amplifications with primers that contained the mutated sequence. The mutated ebi2 DNA was inserted back into the pCIneo vector, and all constructs were verified through DNA sequencing at Eton Bioscience (San Diego, CA). A complete list of mutations is presented in Supplemental Table 1 .
Tissue Culture and Recombinant Expression of Mutant Human EBI2. COS-7 cells were grown in Dulbecco's modified Eagle's medium (Invitrogen; with 4500 mg/liter glucose, 10% fetal bovine serum, 1% penicillin-streptomycin, 1 mM sodium pyruvate, and 20 mM HEPES) at 5% CO 2 and 37°C. Transient transfections of COS-7 cells were performed by using Lipofectamine reagent in Opti-MEM (Invitrogen), according to the manufacturer's instructions. For receptor expression characterization, cells were transiently transfected with V5-tagged ebi2 alone. For GTP␥S and radioligand binding assays, cells were cotransfected with ebi2 constructs plus a human G-protein (G o2 ) expression construct that contained the coding region of human G o2 (GenBank accession no. AF493895) in the mammalian expression vector pcDNA3.1/zeo. The transfected cells were harvested 48 h later, and cell pellets were stored at Ϫ80°C until GTP␥S and radioligand binding assays were performed.
Characterization of Receptor Expression. For assessment of total and cell-surface receptor expression levels, transiently transfected cells were seeded in 96-well culture plates, in triplicate (4 ϫ 10 4 cells/well), 24 h after transfection. Cells were fixed with 4% paraformaldehyde 2 days after transfection. Total and cell-surface expression levels for V5-tagged receptor proteins were quantified with enzyme-linked immunosorbent assays with an anti-V5 antibody (1 g/ml), in the presence of 1% Triton X-100 (for total protein levels) or in the absence of Triton X-100 (for cell-surface protein levels). Cells transfected with the G o2 expression construct alone were used as negative controls. Cells transfected with the wild-type V5-ebi2 construct were used as positive controls. Cells transfected with GPR81-V5, a GPR81 expression construct with a V5 tag at the C terminus, were also included as controls.
GTP␥S Binding Assays. [ 35 S]GTP␥S binding assays were performed as described (Liu et al., 2003 (Liu et al., 2001 (Liu et al., , 2011 . Membrane preparations from COS-7 cells transiently expressing wild-type or mutant EBI2 were incubated with [ 3 H]7␣,25-OHC (100,000 cpm) in the presence of various concentrations of unlabeled 7␣,25-OHC as a competitor. We used unlabeled 7␣,25-OHC as the competitor because it has the highest affinity for EBI2 and the best solubility. We showed previously that unlabeled 7␣,25-OHC (1 M) did not displace binding significantly in mock-transfected COS-7 cells (Liu et al., 2011) . Other available ligands have lower affinities for EBI2 and/or are much more hydrophobic. Use of those ligands at concentrations that saturated EBI2 binding often led to solubility problems. The reaction mixtures were incubated at room temperature for 1 h, filtered though a 96-well GFC filter plate, and washed three times with buffer (20 mM Tris-HCl, 10 mM MgCl 2 , pH 7.4). Bound radioligand levels were assessed with the TopCount NXT counter, and the results were analyzed with GraphPad Prism 5. The maximal level of specific binding of [ 3 H]7␣,25-OHC to wild-type EBI2 was expressed as 100% and was used for comparisons of radioligand binding to mutant receptors. Molecular Modeling. Homology modeling of human EBI2 and subsequent docking of 7␣,25-OHC were performed by using Discovery Studio 3.1 (Accelrys, San Diego, CA). The primary sequence alignment between the human ␤ 2 AR and EBI2 was determined by using the align123 program in Discovery Studio. The helical alignment was further examined and manually refined on the basis of multiple sequence alignments of family A GPCRs (Mirzadegan et al., 2003) . The ␤ 2 AR structure (PDB code 2RH1) was used as a template for EBI2 except for TM2 and ECL2, for which CXCR4 (PDB code 3ODU) was used as a template. Each CXCR4 component was separately aligned with the ␤ 2 AR structure, to yield a hybrid ␤ 2 AR-CXCR4 template structure. On the basis of this hybrid template structure, an EBI2 homology model was built by using the homology modeling component of Discovery Studio. The EBI2 homology model was placed in a 30-Å-thick implicit membrane and was energy-minimized by using the Smart Minimizer algorithm with the generalized Born with implicit membrane/implicit solvent model and the CHARMm force field. 7␣,25-OHC was manually docked into the ligand binding site of the model EBI2 structure on the basis of GTP␥S binding assay and radioligand binding assay data. After the ligand was docked into the binding site, a standard dynamics cascade (including steepest descent minimization, conjugate gradient minimization, heating of the system to 300°K, molecular dynamics equilibration, and production runs) was performed with the ligand constrained. The constraints on the ligand were then removed, and the entire system was further minimized to generate the final model of EBI2 with docked 7␣,25-OHC.
Results
Effects of Ligand Structure on EBI2 Activation.
[ 35 S]GTP␥S binding assays were used for quantification of receptor activation. This type of assay measures the binding of nonhydrolyzable [
35 S]GTP␥S to the G␣ subunit after agonist occupation of the receptor; it has the advantages of measuring one of the earliest receptor-mediated events in the signaling cascade and being less affected by downstream signaling amplification or modulation. We transfected COS-7 cells with EBI2 expression constructs in combination with G o2 protein because our previous studies showed that coexpression of G o2 increased ligand-stimulated [
35 S]GTP␥S incorporation and improved the signal/noise ratio (Liu et al., 2011) .
Previously we showed that 7␣,25-OHC activated EBI2 with high affinity and potency in recombinant systems (K d ϭ 450 pM; EC 50 ϭ 140 pM) (Liu et al., 2011) . We also screened other oxysterols and cholesterol derivatives for their abilities to activate EBI2. We ranked, on the basis of ligand potency, the compounds that showed agonist activity, as follows: 7␣,25-OHC (EC 50 ϭ 0.14 nM) Ͼ 7␣,27-OHC (EC 50 ϭ 1.3 nM) Ͼ 7␤,25-OHC (EC 50 ϭ 2.1 nM) Ͼ 7␤,27-OHC (EC 50 ϭ 51 nM) Ͼ 7␣-OHC (EC 50 ϭ 82 nM) Ͼ 25-OHC (EC 50 ϭ 127 nM) Ͼ 7␤-OHC (EC 50 ϭ 1763 nM) Ͼ 27-OHC (EC 50 ϭ 3029 nM) (Liu et al., 2011) . These findings strongly suggested that the hydroxyl groups in the 7Ј-, 25Ј-, or 27Ј-positions are important for EBI2 activation. It is important to note that cholesterol has a hydroxyl group in the 3Ј-position of the ring structure and this hydroxyl group was present in all of the oxysterols we tested previously. The importance of the 7Ј-and 25Ј-hydroxyl groups for EBI2 activation prompted us to ask whether the third hydroxyl group in 7␣,25-OHC, in the 3Ј-position, also might play a role. To assess the functional significance of the 3Ј-hydroxyl group, we tested 7␣,27-dihydroxy-4-cholesten-3-one, which is structurally similar to 7␣,27-OHC except that its 3Ј-position has a ketone group instead of a hydroxyl group (Fig. 2A) . Consistent with our previous report, 7␣,27-OHC showed high potency in activating EBI2 ( Fig. 2B ; Table 1 ). In contrast, 7␣,27-dihydroxy-4-cholesten-3-one at concentrations up to 10 M showed little activity in stimulating [
35 S]GTP␥S incorporation by EBI2-expressing membranes ( Fig. 2B; Table 1 ), which supports the hypothesis that the 3Ј-hydroxyl group is critical for maintaining agonist activity.
Biochemical Analysis of Receptor Expression Levels for Wild-Type and Mutant EBI2. To quantify receptor expression, we added a V5 tag to the N-terminal region of wild-type and mutant EBI2. In our previous study, we demonstrated that the N-terminal V5 tag did not affect EBI2 signaling (Liu et al., 2011 ). An anti-V5 antibody was used to label receptor proteins in transfected cells. Most mutant receptors showed similar total and cell-surface expression levels, compared with wild-type receptor levels, when protein levels were quantified with enzyme-linked immunosorbent assays (Supplemental Table 1 ). Three mutations, i.e., C104A (ECL1), C181A (ECL2), and F257A (TM6), resulted in ϳ50% reductions in total protein expression levels, compared with wild-type EBI2 levels (Table 2) , which suggests that these three residues may be important for the biosynthesis or protein stability of EBI2. Several mutations, including C21A (N terminus), C104A (ECL1), C181A (ECL2), C280A (ECL3), P85A (TM2), Y90A (TM2), N114A (TM3), and F257A (TM6) ( Table 2) , resulted in substantial reductions in cell-surface receptor expression levels. These residues may be important for proper receptor folding, trafficking, and insertion into the cell membrane.
Investigation of Cysteine Residues in Extracellular Regions of EBI2. There are four Cys residues in the extracellular regions of EBI2, i.e., Cys21 (N terminus), Cys104 (ECL1), Cys181 (ECL2), and Cys280 (ECL3). We mutated these four Cys residues to Ala individually, to determine whether receptor expression, receptor function, and/or ligand binding was affected. The C104A and C181A mutations resulted in complete loss of cell-surface receptor expression but similar total receptor protein levels, compared with wild-type EBI2 values (Table 2) , which suggests that Cys104 and Cys181 may be critical for proper EBI2 folding, trafficking, or insertion into the cell membrane. No signals were detected for these two mutants in GTP␥S binding assays or radioligand binding assays ( Fig. 3A; Table 2 ). Ala substitutions at Cys21 or Cys280 led to 70 to 80% reductions in cell-surface receptor expression levels and ϳ50% reductions in total protein expression levels (Table 2) , which indicates additional roles in receptor biogenesis. In GTP␥S binding assays, the C21A mutation in the N terminus caused a 20-fold increase in the EC 50 of 7␣,25-OHC and a ϳ75% decrease in E max , compared with wild-type EBI2 values ( Fig. 3A; Table 2 ). We did not detect any specific binding signals for the C21A mutant receptor, probably because of reduced ligand binding affinity and reduced cell-surface receptor expression. The C280A mutation in ECL3 resulted in relatively more-moderate reductions in receptor activity (EC 50 ϭ 0.93 nM for [ 35 S]GTP␥S incorporation) (Fig. 3A) and radioligand binding (16.56% of the wild-type EBI2 value) ( Table 2) . binding and/or receptor activation. We compared human, rat, and mouse EBI2 sequences (Fig. 1A) and selected a number of conserved residues for mutagenesis studies (Fig. 1B) . For example, the ECL2 contains a highly conserved region in positions 180 to 188, i.e., TCMEYPNFE. We made single Ala substitutions at these positions and characterized the mutant receptors pharmacologically. We also included in our study two single-nucleotide polymorphisms in the extracellular region, i.e., M93I (ECL1) and H284Y (ECL3), as listed in the National Institutes of Health National Center for Biotechnology Information single-nucleotide polymorphism database (www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusIdϭ 1880). Our results showed that most of the mutants had comparable levels of receptor expression and similar pharmacological profiles, compared with wild-type EBI2 (Table 2;  Supplemental Table 1 ). In addition to Cys181, as mentioned above, we found that Ala substitution for Glu183 in ECL2 resulted in great reduction in the radioligand binding signal (11.33% of the wild-type value), although cell-surface expression was only moderately decreased (59.82% of the wild-type value) ( Table 2 ). In agreement with the radioligand binding data, the E183A mutation resulted in an almost 50-fold reduction in ligand potency in GTP␥S binding assays ( Fig. 3B ; Table 2 ).
Mutations of Conserved Residues in Extracellular
Mutation Studies with Transmembrane Regions of EBI2. Transmembrane regions of GPCRs are highly conserved structurally, and the helical cores are thought to form the ligand binding pocket. On the basis of a method developed by Mirzadegan et al. (2003) , we performed sequence alignments of EBI2 with GPCRs that have known crystal structures and well characterized ligand binding sites. Residues in EBI2 that were aligned at the sequence positions corresponding to the known ligand binding sites of GPCRs were selected for our mutation study (Fig. 1B) . at ASPET Journals on July 24, 2017 molpharm.aspetjournals.org
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As noted above, the P85A (TM2), Y90A (TM2), N114A (TM3), and F257A (TM6) mutations resulted in Ն50% reductions in cell-surface receptor expression levels. Although the N114A mutant still exhibited a 50% cell-surface expression level, its maximal radioligand binding level was only ϳ15.98%, compared with the wild-type values. Moreover, this mutant receptor was nonfunctional, because no GTP␥S binding could be detected even with 1 M 7␣,25-OHC ( Fig.  3D ; Table 2 ).
We also found a series of mutations in the transmembrane regions that did not affect cell-surface receptor expression levels but had negative effects on receptor activity in GTP␥S assays ( Fig. 3; Table 2 ). To understand whether the functional disruption was attributable to the inability to bind 7␣,25-OHC, we tested these mutants in radioligand binding assays. For comparison of ligand binding levels, we were able to perform only competitive radioligand binding assays, rather than saturation binding assays, because of the limited stock of [ 3 H]7␣,25-OHC available and the large collection of mutants we generated. We confirmed that almost all of the mutants exhibited reduced or abolished [ 3 H]7␣,25-OHC binding. For example, when Arg87 in TM2 was mutated to Ala or Trp, radioligand binding was greatly decreased (3% or 17.59% of the wild-type value, respectively). Consequently, the ligand potency in GTP␥S binding assays was reduced 449-or 582-fold, respectively. Mutation of Arg87 to Lys, another amino acid with a positively charged side chain, did not have any significant effect on receptor activity or ligand binding. Arg87 has been reported to be important for the constitutive activity of EBI2, and we did not assess the constitutive activity of EBI2 in this study. However, our result suggests that Arg87 is important for ligand activation of EBI2. Other transmembrane region residues that showed reduced ligand binding and receptor function after Ala mutation included Tyr112 and Tyr116 of TM3, Leu197 of TM5, Tyr260, His261, and Ile264 of TM6, and Val294 and Met297 of TM7 (Table 2) .
Importance of Asp77 in TM2 for Receptor Activation. The majority of mutations that negatively affected receptor activation were found to be important also for ligand binding. Receptors with the single amino acid change of Asp77 in TM2 to Ala retained normal ligand binding (Table 2) . Asp77 is not involved in receptor biogenesis or trafficking, inasmuch as both cell-surface and total protein expression levels were similar to wild-type EBI2 levels (Table 2) . However, this mutant receptor showed no [ 35 S]GTP␥S incorporation even with 1 M 7␣,25-OHC ( Fig. 3E ; Table 2 ). Such a pharmacological profile suggests that Asp77 is not involved in ligand binding but might be important for receptor activation or signal transduction. The aspartic acid in TM2 is a highly conserved residue among family A GPCRs. In the available GPCR crystal structures, this aspartic acid lies below the ligand binding site in what is considered a water channel, and it is important for transmission of the signal upon ligand binding to the G-protein binding site on the intracellular side of the GPCR (Angel et al., 2009) .
Homology Modeling of Human EBI2 and Ligand Docking. The ␤ 2 AR structure (PDB code 2RH1) (Cherezov et al., 2007) has 52.9% sequence similarity to EBI2 in the transmembrane regions. Therefore, it was used as a template for building of the homology model. During manual refinement after multiple sequence alignments with family A GPCRs 
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at ASPET Journals on July 24, 2017 molpharm.aspetjournals.org (Mirzadegan et al., 2003) , we found that TM2 of EBI2 exhibits structural features similar to those of CXCR4 (PDB code 3ODU) because of the proline residue in this region (Pro85 in EBI2 and Pro92 in CXCR4) (Fig. 4A ). In addition, ECL2 of EBI2 exhibits greater sequence similarity to CXCR4 (35%) than to ␤ 2 AR (24%) (Fig. 4B) . Therefore, CXCR4 was used as the template structure for the TM2 and ECL2 regions of EBI2. For modeling of the ligand binding site, 7␣,25-OHC was manually docked on the basis of results from our structure-activity studies. The three hydroxyl groups (in the 3Ј-, 7Ј-, and 25Ј-positions) of 7␣,25-OHC were determined to be essential for receptor-ligand interactions and were used to orient the ligand. The final model of EBI2 with 7␣,25-OHC docked is shown in Fig. 4 , C and D. As illustrated in our proposed model, Arg87 of EBI2 interacts with the 7␣Ј-hydroxyl group of 7␣,25-OHC, Asn114 interacts with the 25Ј-hydroxyl group, and Glu183 interacts with the 3Ј-hydroxyl group. Asp77 lies just below the modeled ligand binding site and likely plays a role in signal transmission and receptor activation. Residues Tyr112, Tyr116, Leu197, His261, Val294, and Met297 form hydrophobic interactions with the steroidal body of 7␣,25-OHC.
Discussion
Importance of 7␣,25-OHC Hydroxyl Groups for Receptor Activation. The identification of 7␣,25-OHC as the endogenous ligand for EBI2 provides a pharmacological tool for activation of the receptor in vitro and investigation of the molecular mechanisms underlying EBI2 activation (Hannedouche et al., 2011; Liu et al., 2011) . Here we used a mutagenesis approach to identify the residues in EBI2 that are Table 2 . Membranes from cells expressing wild-type (WT) human EBI2 and cells transfected with only G o2 were used as the positive control and negative control (NC), respectively. critical for receptor function or ligand binding. We previously tested more than 40 oxysterols and cholesterol derivatives with EBI2 and validated 7␣,25-OHC as the most potent ligand. We also were able to extrapolate structure-activity correlations from these results, to help elucidate the key molecular drivers involved in ligand activation. Oxysterols are oxygenated derivatives of cholesterol. Although cholesterol was completely inactive with EBI2, the addition of a hydroxyl group to the steroidal ring structure (as in 7␣-OHC and 7␤-OHC) or to the hydrocarbon tail (as in 25-OHC or 27-OHC) was able to confer agonist activity, with EC 50 values ranging from 100 nM to low micromolar levels (Hannedouche et al., 2011; Liu et al., 2011) . Dihydroxycholesterols with two additional hydroxyl groups, compared with cholesterol (e.g., 7␣, 7␤, 7␣, and 7␤, , were found to activate EBI2 with much greater potency. The position of the hydroxyl group is also a critical determinant. To our knowledge, addition of a hydroxyl group to the 4Ј-, 5Ј-, 6Ј-, 15Ј-, 22Ј-, or 24Ј-position was unable to induce any agonist activity (Liu et al., 2011) . It is possible that only the 7Ј-, 25Ј-, and 27Ј-positions allow the hydroxyl groups to adopt the correct conformations for contacting key residues in the ligand binding site and forming optimal hydrogen bond interactions. The rank order of active oxysterols on the basis of functional potency (7␣,25-OHC Ͼ 7␣,27-OHC Ͼ 7␤,25-OHC Ͼ 7␤,27-OHC Ͼ 7␣-OHC Ͼ 25-OHC Ͼ 7␤-OHC Ͼ 27-OHC) correlates well with their binding affinities. It is reasonable to postulate that, to achieve the optimal interactions between the receptor and ligands, a hydroxyl group in the 7␣Ј-position has a more-favorable conformation than one in the 7␤Ј-position and a second hydroxyl group in the 25Ј-position is more favorable than one in the 27Ј-position.
The 3Ј-hydroxyl group is native to cholesterol and is present in all of the other oxysterols we tested. Although 7␣,27-OHC was the second most potent agonist for EBI2, the substitution of the 3Ј-hydroxyl group with a ketone group abolished the ability to activate EBI2. Taken together, these findings indicate that all three hydroxyl groups (3Ј, 7␣Ј, and 25Ј) in 7␣,25-OHC are involved in ligand binding and receptor activation, and the positions and orientations of the hydroxyl groups play key roles in determining agonist activity.
Evidence that Glu183 in ECL2 Is Held by Classic Disulfide Bridge and Caps Ligand Binding Site. Certain structural features are conserved among almost all members Fig. 4 . A, sequence alignment of EBI2 transmembrane helix 2 with those of ␤ 2 AR and CXCR4. CXCR4 was chosen as the template for the modeling of EBI2 helix 2 because of the position of the proline at position 21, compared with position 22 in the ␤ 2 AR. B, sequence alignment of EBI2 extracellular loop 2 with those of ␤ 2 AR and CXCR4. C, homology model of EBI2 with docked 7␣,25-OHC. The homology model was created by using CXCR4 (PDB code 3ODU) as a template for helix 2 and ECL2. Each of the CXCR4 segments was separately aligned with the ␤ 2 AR (PDB code 2RH1), which was used as a template for the remaining helices and loops. 7␣,25-OHC was manually docked in the EBI2 homology model by using available structure-activity relationship data. The hydroxyl groups of 7␣,25-OHC interact with residues Arg87, Asn114, and Glu183 on EBI2. Residue Asn77 is not involved in ligand binding but is highly conserved and is important for transmission of the GPCR signal. The disulfide bond formed by Cys104 and Cys181 is structurally important in maintaining the position of the ECL2 loop, which partially caps the ligand binding site, and the positioning of Glu183. D, close-up view of the ligand binding site of EBI2. 7␣,25-OHC is oriented in the binding site of EBI2 with the 25Ј-hydroxyl group interacting with the Asn144 carboxamide group, the 7␣Ј-hydroxyl group interacting with the Arg87 guanidinium group, and the 3Ј-hydroxyl group (native to cholesterol) interacting with the Glu183 carboxylate group. The remaining residues, i.e., Tyr112, Tyr116, Leu197, His261, Val294, and Met297, form hydrophobic interactions with the steroidal body of 7␣,25-OHC.
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at ASPET Journals on July 24, 2017 molpharm.aspetjournals.org of the GPCR superfamily, one of which is a disulfide bridge formed between a conserved Cys residue in ECL2 and another conserved Cys residue in ECL1 near the top of TM3 (Gether 2000; Karnik et al., 2003) . This covalent linkage, which is present in Ͼ90% of all GPCRs, is acknowledged to be important for the tertiary integrity of GPCRs, ligand gating, and even ligand binding (Klco et al., 2005) . Our data suggest that Cys104 and Cys181 are functionally more equivalent, whereas Cys21 is more similar to Cys280, which supports our hypothesis that Cys104 (ECL1) and Cys181 (ECL2) form the classic disulfide bond, whereas Cys21 (N terminus) and Cys280 (ECL3) may form a second disulfide bridge. This pattern of extracellular disulfide bridges is the same as in CXCR4, which also has four extracellular Cys residues distributed in the N terminus, ECL1, ECL2, and ECL3. The crystal structure of CXCR4 confirmed the two disulfide bridges, i.e., Cys109-Cys186 linking ECL2 with the extracellular end of TM3 and Cys28-Cys274 connecting the N terminus to the extracellular tip of TM7 (Wu et al., 2010 ).
This proposed model of two disulfide bridges has important functional implications. Because of the Cys104-Cys181 link, ECL2 is brought close to the transmembrane domain and may form a cap over the putative ligand binding site (Fig.  4C ), similar to findings observed for most GPCRs. ECL2 thus may be positioned to interact with the ligand. Glu183, which is just two residues from Cys181, is the best candidate for forming a hydrogen bond with one of the hydroxyl groups of 7␣,25-OHC. Our mutagenesis data confirmed that Ala substitution at Glu183 disrupted ligand binding and receptor activity ( Fig. 3B; Table 2 ), which supports our hypothesis that Glu183 is held by the disulfide bridge over the ligand binding pocket so that the hydroxyl group of 7␣,25-OHC can interact with the Glu183 carboxylate group. The inactivity of 7␣,27-dihydroxy-4-cholesten-3-one provided more evidence that the 3Ј-hydroxyl group interacts with Glu183, because a ketone interacting with the carboxylate would be energetically unfavorable. Taken together, the results suggest an important structural role for ECL2 in ligand activation of EBI2.
Molecular Modeling of Ligand Binding Pocket of EBI2. EBI2 is the first GPCR known to bind an oxysterol as an endogenous ligand (Hannedouche et al., 2011; Liu et al., 2011) . Therefore, it is of particular interest to understand how 7␣,25-OHC interacts with EBI2 and which molecular determinants are critical for this interaction. The ␤ 2 AR structure (PDB code 2RH1) has 52.9% sequence similarity to EBI2 in the transmembrane regions and was used as a template for building the EBI2 homology model. For EBI2 TM2, however, CXCR4 TM2 was chosen over the ␤ 2 AR as a template, because Pro85 in EBI2 TM2 aligns with Pro92 in CXCR4 TM2, whereas the proline in the ␤ 2 AR (Pro88) is shifted by one residue (Fig. 4A) . Proline residues break helical secondary structures, which produces a kink in the helix. Shifting a proline residue by even a single position would cause the remaining helix to be kinked in a slightly different orientation. Arg87, which lies two residues above Pro85, was crucial for ligand binding. Therefore, we used CXCR4 TM2 as a template to ensure that the helix would be kinked in the correct position and the remaining downstream residues, including Arg87, would be in the proper orientation. The crystal structures of GPCRs show very different ECL2 structures. ECL2 of CXCR4 was chosen as the template for EBI2 because it has similar length and greater sequence similarity (35%) with respect to EBI2, among the available GPCRs with known crystal structures (Fig. 4B ). This created a hybrid structure in which the ␤ 2 AR was used as the base structure, whereas TM2 was kinked and ECL2 was modeled as in CXCR4. The use of a hybrid template for GPCR homology modeling was reported previously (Worth et al., 2009 (Worth et al., , 2011 .
After the EBI2 homology model based on the hybrid ␤ 2 AR-CXCR4 template was built, 7␣,25-OHC was manually docked into the ligand binding site. Of all residues that were identified as being important for ligand binding, Arg87, Asn114, and Glu183 are polar or charged residues that might interact with the three hydroxyl groups in 7␣,25-OHC. As expected, alanine mutations for Arg87, Asn114, and Glu183 led to functional disruption and were subsequently used to orient the ligand and to optimize the EBI2 homology model (Fig. 4) . In the final docked model, 7␣,25-OHC is oriented with the 25Ј-hydroxyl group interacting with the Asn144 carboxamide group, the 7␣Ј-hydroxyl group interacting with the Arg87 guanidinium group, and the 3Ј-hydroxyl group (native to cholesterol) interacting with the Glu183 carboxylate group (Fig. 4, C and D) . The orientation of Arg87 with the 7␣Ј-hydroxyl group is consistent with the observation that 7␣,25-OHC is more potent than 7␤,25-OHC in activating EBI2. Because the steroidal body of 7␣,25-OHC is rigid, a hydroxyl group in the 7␤Ј-conformation would be constrained, which would hinder optimal contact with the guanidinium group in Arg87. It was reported previously that Arg87 might act as a positive regulator for the constitutive activity of EBI2, because substitution of Arg87 with Ala but not Lys significantly reduced constitutive activity (Benned-Jensen and Rosenkilde, 2008) . This is in line with our finding that the R87A mutation but not the R87K mutation resulted in reduced ligand activation, which suggests that Arg87 may serve as an important molecular switch between the inactive and active states of EBI2.
The interaction between Asn114 and the 25Ј-hydroxyl group provides the structural basis for the better potency of 7␣,25-OHC, compared with 7␣,27-OHC, because the hydroxyl group at the 27Ј-position would not reach as close to Asn114 for optimal interactions. Other evidence supporting the putative orientation of 7␣,25-OHC includes the observation that the M297I mutation but not the M297A mutation decreased ligand binding. In the docked homology model, M297 lies tight against the steroidal body of 7␣,25-OHC. A more-bulky, branched-chain amino acid such as Ile at this position would have unfavorable steric interactions with the rigid steroidal ring structure of the ligand.
In conclusion, our results suggest that all three hydroxyl groups (3Ј, 7␣Ј, and 25Ј) of the ligand are important for receptor binding and activation, with the 3Ј-hydroxyl group interacting with Glu183, the 7␣Ј-hydroxyl group interacting with Arg87, and the 25Ј-hydroxyl group interacting with Asn114. The proposed EBI2 homology model described in this report includes the critical chemical and structural features of the binding pocket and may be useful for future, structure-based, drug-discovery efforts.
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